| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Chief Accounting Officer | SVP, Chief Accounting Officer | VP, Corp Controller and CAO
1 company
Calvin Sandra serves as a SVP, Chief Accounting Officer at TVTX. Across recent SEC filings that breaks down to 0 buys and 30 sells. Those positions are worth an estimated $2.7M at current prices.
Historically, Calvin Sandra's trades have earned a middling insider score of 60/100 across 22 rated trades. Over a 12-month horizon, 61.1% of those trades were profitable, with an average 12-month return of -2.5%.
The biggest single holding is TVTX (~$2.7M) as SVP, Chief Accounting Officer. The recent filings there lean toward selling, a net 205,097 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE10b5-1 | 5,375 | $62.33 | $335,004.60 | -11.3% | - | - | |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE10b5-1 | 21,977 | $41.07 | $902,595.39 | -34.2% | +33.6% | - | |
| Feb 3, 2026 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 4,333 | $32.12 | $139,175.96 | -8.1% | +36.8% | - | |
| Dec 24, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell10b5-1 | 7,402 | $40.00 | $296,080.00 | -16.2% | -33.5% | - | |
| Dec 15, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell10b5-1 | 2,910 | $36.00 | $104,760.00 | -6.0% | -19.4% | - | |
| Nov 4, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE10b5-1 | 67,115 | $36.00 | $2,416,140.00 | -58.0% | -3.0% | - | |
| Feb 11, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE10b5-1 | 54,244 | $25.00 | $1,356,100.00 | -49.9% | -9.3% | +27.2% | |
| Feb 3, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 3,348 | $20.12 | $67,361.76 | -5.0% | +5.9% | +62.4% | |
| Jan 22, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 925 | $18.94 | $17,520.24 | -1.7% | -18.4% | +52.8% | |
| Dec 26, 2024 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE10b5-1 | 15,000 | $17.22 | $258,277.50 | -21.5% | +16.9% | +122.9% |